Epredia

Epredia specializes in precision diagnostic solutions for pathology laboratories, delivering a comprehensive range of products designed to enhance diagnostic accuracy and streamline laboratory workflows. Epredia provides precision diagnostic solutions for pathology laboratories, having been established in Kalamazoo, US in 2019. The company was formed following the acquisition of the Anatomical Pathology business of Thermo Fisher Scientific Inc. by PHC Holding Group for USD 1.

14 billion, which was completed in June 2019. The deal led to the renaming of the company to Epredia. John Marotta serves as the CEO of the company, guiding its operations and strategic direction. Epredia specializes in precision diagnostic solutions for pathology laboratories, offering products that include high-resolution slide printing systems, tissue processing solutions, and cryostats.

Their innovations, such as the SlideMate Laser, support efficient laboratory workflows and improve diagnostic accuracy. Products are utilized by hospitals, research institutions, and diagnostic laboratories in North America, Europe, and Asia-Pacific, addressing the needs of histology, immunohistochemistry, and digital pathology. In the most recent fiscal year, Epredia generated revenue of USD 350,000,000. The company earns this revenue through direct sales of its diagnostic products and services to healthcare facilities and research institutions.

Key products like the E1000 Dx Digital Pathology Solution contribute significantly to their revenue model, which operates primarily on a business-to-business (B2B) sales structure. Epredia aims to launch new diagnostic products in the upcoming years, with specific details on release dates to be announced. The company is strategically planning to expand its operations into new geographic regions, focusing on markets in Europe and Asia-Pacific by 2025. Recent funding from the acquisition transaction will be utilized to support these initiatives, enhancing product development and market penetration.